Initial hypertension treatment: one combination fits most
Journal of the American Society of Hypertension, 03/23/2011
Brook RD et al. - Authors outline a novel algorithm of starting initial therapy with a single tablet containing amlodipine + benazepril in most patients with hypertension regardless of stage or comorbidities. This streamlined approach is likely to yield an overall positive risk/benefit ratio.
Authors reviewed published studies related to the efficacy and efficiency of starting combination antihypertensive treatment versus mono-therapy.
The evidence supports that initial combination therapy is more effective for many outcomes (ie, reaching blood pressure targets, rapidity of control, patient adherence, and cardiovascular protection assessed by surrogate markers).
The few available published clinical trials and observational studies support that the amlodipine + an angiotensin-converting enzyme inhibitor combination may be the most effective for reducing cardiovascular events.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.